NEW YORK (GenomeWeb) – Cancer informatics and precision medicine firm Tempus said today that it has raised $110 million in a Series E financing round.

Participants in the round included Baillie Gifford, funds and accounts managed by T. Rowe Price, Revolution Growth, New Enterprise Associates, and other existing investors.

Tempus, based in Chicago, said that it will use the additional funds to grow operations and expand into new therapeutic areas and geographies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.